Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

BeiGene Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Public

Established: 2010-01-01

Employees: 10K

Market Cap: $22.1B

Website: http://www.beigene.com

Clinical Trials

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Phase 3

Completed

Conditions: Gastric, or Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Tislelizumab
Drug: Placebo
Drug: Cisplatin
Drug: Oxaliplatin
Drug: Capecitabine
Drug: 5-Fluorouracil

First Posted Date: 2018-12-17

Last Posted Date: 2025-03-25

Lead Sponsor: BeiGene

Target Recruit Count: 997

Registration Number: NCT03777657

Locations: 🇨🇳
Foshan First Peoples Hospital, Foshan, Guangdong, China
🇨🇳
Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China

and more 146 locations

Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1

Completed

Conditions: Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2

Interventions: Drug: BGB-A425
Drug: Tislelizumab
Drug: LBL-007

First Posted Date: 2018-11-16

Last Posted Date: 2025-02-14

Lead Sponsor: BeiGene

Target Recruit Count: 114

Registration Number: NCT03744468

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

and more 39 locations

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Phase 2

Recruiting

Conditions: MSI-H/dMMR Solid Tumors

Interventions: Drug: Tislelizumab (BGB-A317)

First Posted Date: 2018-11-09

Last Posted Date: 2024-12-06

Lead Sponsor: BeiGene

Target Recruit Count: 200

Registration Number: NCT03736889

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
The Affiliated Hospital of Military Medical Sciences, Beijing, Beijing, China
🇨🇳
Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China

and more 26 locations

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Phase 3

Completed

Conditions: Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Drug: Zanubrutinib
Drug: Ibrutinib

First Posted Date: 2018-11-07

Last Posted Date: 2025-03-30

Lead Sponsor: BeiGene

Target Recruit Count: 652

Registration Number: NCT03734016

Locations: 🇬🇧
Barts Health Nhs Trust, London, United Kingdom
🇬🇧
Genesiscare Oxford, Waterlooville, United Kingdom
🇺🇸
Carti Cancer Center, Little Rock, Arkansas, United States

and more 112 locations

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Phase 2

Terminated

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Homologous Recombination Deficiency (HRD)

Interventions: Drug: Pamiparib

First Posted Date: 2018-10-19

Last Posted Date: 2021-11-17

Lead Sponsor: BeiGene

Target Recruit Count: 13

Registration Number: NCT03712930

Locations: 🇺🇸
University Cancer and Blood Center, Athens, Georgia, United States
🇺🇸
Montefiore Einstein Cancer Center, Bronx, New York, United States
🇺🇸
University of Washington, Seattle, Washington, United States

and more 6 locations

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Sitravatinib
Drug: Tislelizumab

First Posted Date: 2018-09-11

Last Posted Date: 2024-11-04

Lead Sponsor: BeiGene

Target Recruit Count: 216

Registration Number: NCT03666143

Locations: 🇦🇺
Icon Cancer Foundation, South Brisbane, Queensland, Australia
🇦🇺
Austin Health, Heidelberg, Victoria, Australia
🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia

and more 16 locations

A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Tislelizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2018-09-10

Last Posted Date: 2025-02-04

Lead Sponsor: BeiGene

Target Recruit Count: 334

Registration Number: NCT03663205

Locations: 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

and more 44 locations

The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: BGB-283

First Posted Date: 2018-08-22

Last Posted Date: 2024-10-23

Lead Sponsor: BeiGene

Target Recruit Count: 42

Registration Number: NCT03641586

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Paclitaxel
Drug: Tislelizumab
Drug: Nab-paclitaxel
Drug: Carboplatin

First Posted Date: 2018-07-20

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 360

Registration Number: NCT03594747

Locations: 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

and more 48 locations

Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

Phase 2

Completed

Conditions: HER2-negative Breast Cancer

Interventions: Drug: BGB-290

First Posted Date: 2018-07-02

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 88

Registration Number: NCT03575065

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou, Guangdong, China
🇨🇳
Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China

and more 17 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy